News
Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preliminary results from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a
IMV Inc. to Announce Third Quarter 2021 Results and Host a Conference Call and Webcast on November 11, 2021
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating cancer therapies, based on its novel DPX platform, to treat solid and blood cancers while
QIAGEN Reports Strong Results for Third Quarter and First Nine Months Of 2021
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the third quarter and first nine months of 2021.
In Q3 2021, net sales rose 11% (+10% at constant exchange rates
Navidea Biopharmaceuticals to Host Third Quarter 2021 Earnings Conference Call and Business Update
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Conference
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
QIAGEN meldet starke Ergebnisse für das dritte Quartal und die ersten neun Monate 2021
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Ergebnisse für das dritte Quartal und die ersten neun Monate 2021 bekannt.
Der Konzernumsatz stieg im dritten Quartal 2021 um
Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Clovis Oncology Announces Third Quarter 2021 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2021, and provided an update on the Company’s clinical development programs and regulatory and
Ipsen Appoints Stewart Campbell Executive Vice President and President of North America
Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Stewart Campbell as Executive Vice President and President of North America, effective immediately. Based in Cambridge, he will
Charles River Laboratories Announces Third-Quarter 2021 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2021. For the quarter, revenue was $895.9 million, an increase of 20.5% from $743.3
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today issued its financial results for the third quarter ended September 30, 2021. Amounts, unless specified otherwise, are
Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in November
POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
QIAGEN expands QIAstat-Dx testing menu with respiratory four-plex panel that differentiates between flu, RSV and SARS-CoV-2
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch and CE-marking of the QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test for the QIAstat-Dx system to quickly
QIAGEN erweitert das QIAstat-Dx-Testmenü um ein 4-Plex-Atemwegs-Panel zur Differenzierung zwischen Grippe-A- und B-Viren, RSV und SARS-CoV-2
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass der QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 Test für das QIAstat-Dx-System, mit dem innerhalb kurzer
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update.
“In the third quarter, we made
PFIZER REPORTS THIRD-QUARTER 2021 RESULTS
Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2021 and raised 2021 guidance(4) for revenues and Adjusted diluted EPS(3) reflecting the net impact of its updated expectations
Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharma company committed to delivering therapeutics that change the course of autoimmune disease, today announced updated
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use the Pfizer-BioNTech COVID-19 Vaccine for
Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2021 financial results on Thursday, November
Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update
Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2021, highlighting commercial strength and strategic investment across clinical, product development and
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer
Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with